Simplify Genomics adds Alzheimer’s risk, broader drug insights in GCR v10

Simplify Genomics on Sept. 15, 2026, launched Version 10 of its Genomic Clinical Report, adding a dedicated Alzheimer’s disease risk assessment, broader pharmacogenomics coverage and new wellness insights. The update expands how the company’s whole-genome platform can be reused as clinical evidence and guidelines change.

Why it matters: - GCR v10 widens the clinical use of a patient’s whole-genome data without requiring a new test for each new question. - The update adds more risk context for Alzheimer’s disease, more medication-response coverage and more health insights that physicians can use alongside other clinical data. - Simplify Genomics is positioning whole-genome sequencing as a reusable source of genomic intelligence as evidence evolves.

What happened: - Simplify Genomics announced Version 10 of its Genomic Clinical Report on Sept. 15, 2026. - The report was developed in Simplify Genomics’ CAP-accredited and CLIA-certified laboratory. - The company was spun out of Human Longevity, Inc. in 2022. - GCR v10 adds a dedicated Alzheimer’s Disease Risk assessment. - The release expands pharmacogenomics coverage from 19 genes and 135 medications to 27 genes and 224 medications. - The report also adds three new wellness insights.

The details: - The Alzheimer’s section reports phased APOE e2, e3 and e4 genotypes and a 20-variant polygenic risk score. - The report can also evaluate rare variants tied to hereditary Alzheimer’s disease, including variants in APP, PSEN1 and PSEN2, through hereditary disease analysis. - New and expanded pharmacogenomics content includes PCSK9, OPRM1, CYP3A4, CFTR, F2, F5 and IFNL3. - The expanded drug coverage reaches cardiovascular medicine, oncology, pain management and other therapeutic areas. - PCSK9 content adds context for inherited lipid disorders and for therapies including evolocumab, alirocumab and inclisiran. - Expanded opioid-related pharmacogenomics includes associations relevant to morphine and fentanyl. - The new GLP-1 receptor agonist response assessment looks at GLP1R variants linked in published studies to differences in glycemic and weight-loss response. - The wellness update also adds genetic insights related to susceptibility to non-alcoholic fatty liver disease. - Another new insight covers the SERPINE1 4G/5G polymorphism, which published studies have linked to venous thromboembolism and myocardial infarction risk. - The company says these findings are meant to complement clinical history, lab results, lifestyle and other risk factors. - Simplify Genomics’ Smart Genome™ platform is designed to let existing genomic data be reanalyzed as new findings emerge.

Between the lines: - The release reflects a shift from one-time genetic reporting toward ongoing interpretation of the same genome over time. - The Alzheimer’s addition is notable because it combines APOE, a polygenic score and hereditary variant review in one report. - The broader medication coverage suggests the company is trying to make genomic reporting more useful across routine care, not just specialty genetics. - The company frames the platform as an “intelligence layer” built on top of sequencing, not just a lab report.

What’s next: - Simplify Genomics is likely to keep adding evidence-driven updates as new associations, guidelines and drug markers emerge. - Existing genomic data on the platform can be revisited as the company expands its reporting and interpretation layers. - The company directs readers to learn more about its Smart Genome platform.

The bottom line: - GCR v10 turns a whole-genome test into a more expansive and reusable clinical tool, with Alzheimer’s risk, broader pharmacogenomics and added wellness insights in one update.